Topics
Glioblastoma | Treatment | Targeted therapy | Botensilimab
Home > Publications > Topics > Glioblastoma > Treatment > Targeted therapy > Botensilimab
Kim KS, Habashy K, Gould A, Zhao J, Najem H, Amidei C, Saganty R,
Arrieta VA, Dmello C, Chen L, Zhang DY, Castro B, Billingham L,
Levey D, Huber O, Marques M, Savitsky DA, Morin BM, Muzzio M,
Canney M, Horbinski C, Zhang P, Miska J, Padney S, Zhang B,
Rabadan R, Phillips JJ, Butowski N, Heimberger AB, Hu J, Stupp R,
Chand D, Lee-Chang C, Sonabend AM.
Fc-enhanced
anti-CTLA-4, anti-PD-1, doxorubicin,
and ultrasound-mediated BBB opening: A novel combinatorial
immunotherapy regimen for gliomas.
Neuro
Oncol. 2024 Jul 19:noae135. doi:
10.1093/neuonc/noae135. PMID:
39028616. Laboratory investigation˰
ˍ